Jeffrey A. Allen, MD

University of Minnesota
BIO

Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis. After completion of his residency training at Tufts University and fellowship in neuromuscular medicine at Harvard Medical School, Dr. Allen joined the faculty at Northwestern University in Chicago. In 2014 he moved to the University of Minnesota, but still holds an adjunct appointment at Northwestern and continues to see patients with inflammatory neuropathy in Chicago on a limited basis. In Minnesota Dr. Allen attends a dynamic neuromuscular clinic, with a clinical focus on peripheral neuropathy, myasthenia gravis, and muscle disorders. He has a particular interest in acquired inflammatory neuropathies, and recently successfully speared an effort to have the University of Minnesota named as a certified Center of Excellence by the GBS/CIDP International Foundation. Dr. Allen’s research efforts have focused on improving the diagnosis and treatment of patients with inflammatory neuropathy.
VIDEO & RESOURCES

  • 12:30
    Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
    Understand the challenges associated with accurately diagnosing CIDP
  • 12:50
    Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
    Review options for individualizing treatment and tools used to assess IgG performance
  • 03:32
    CIDP Assessment Tools: INCAT
    Learn about the The INCAT scores and variations of them used to evaluate outcome measures for immune-mediated neuropathies
  • 01:52
    CIDP Assessment Tools: Grip Strength
    Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP
  • 02:15
    CIDP Assessment Tools: Rasch Overall Disability Score
    Hear a brief description of the Rasch version of the Overall Disability Score used in CIDP diagnosis and treatment
  • 02:11
    CIDP Assessment Tools: Medical Research Council Sum Score
    Understand how the Medical Research Council (MRC) Sum Score can be used for evaluating muscle strength in CIDP
  • 12:15
    The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
    Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
Mel Berger, MD, PhD
Mel Berger, MD, PhD

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring
BIO

Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland. He completed his internship and residency in pediatrics at Boston Children’s Hospital. He did an allergy-clinical immunology fellowship at NIH, and is Board Certified in Pediatrics and Allergy-Immunology. He served as Assistant Chief of Allergy-Immunology at Walter Reed Army Medical Center and had an initial faculty appointment at the Uniformed Services University of Health Sciences.

In 1984, he returned to Cleveland and joined the faculty of Case Western Reserve as Chief of the Division of Allergy-Immunology at Rainbow, Babies and Children’s Hospital and he rose to Professor of Pediatrics, Pathology and General Medical Sciences (Oncology). In 2008, Dr. Berger joined CSL Behring, but he continues to hold a faculty appointment at Case. He served for more than 20 years in the US Army and Army Reserve, including commanding a hospital unit during the peace effort in former Yugoslavia, and retired from the Army as a Colonel.

Dr. Berger's research has focused on control of inflammatory responses and on antigen-antibody and complement interactions, particularly in primary immune deficiency diseases and cystic fibrosis. He has been a leader in research on the clinical use of immunoglobulins and played a key role in developing the use of portable pumps to give IgG subcutaneously. He has published more than 100 peer-reviewed papers on his research, as well as numerous chapters and review articles.

Dr. Berger is a Fellow of the American Academy of Allergy Asthma and Immunology, the American Pediatric Society, and the American Academy of Pediatrics. He has been elected to the American Society for Clinical Investigation and the Society for Pediatric Research, and has served as a Director of the American Board of Allergy and Immunology and on numerous FDA and NIH panels.

VIDEO & RESOURCES

  • 8:25
    Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

    Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

Vera Bril, BSc, FRCPC, MD
Vera Bril, BSc, FRCPC, MD

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada
BIO

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology. She has particular expertise in the diagnosis and management of patients with complex neuromuscular disorders. Her research interests have centered on the diagnosis and evidence-based treatment of myasthenia gravis, inflammatory polyneuropathies, and diabetic sensorimotor polyneuropathy. Her work has helped set the standards for electrophysiological investigations in the definition and evaluation of the progression of chronic polyneuropathies. Her research has helped establish the role of intravenous immunoglobulin in the treatment of myasthenia gravis and the Guillain-Barré Syndrome, and the long-term treatment of chronic inflammatory demyelinating polyneuropathy.

She has acted in an advisory capacity to Health Canada and the FDA. Dr Bril also serves as the Deputy Physician-in-Chief for Economic Affairs for the Department of Medicine at the University Health Network and Mount Sinai Hospital and Chair of the Economics committee. She is part of the Department of Medicine Executive Committee and helps administer this group of 300 physicians.

VIDEO & RESOURCES

  • 15:31
    20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
    Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
  • 5:24
    Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

Peter Donofrio, MD
Peter Donofrio, MD

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA
BIO

Peter D. Donofrio, M.D. is a Professor of Neurology at Vanderbilt University Medical Center. He is a graduate of The Ohio State University School of Medicine and pursued a residency in neurology and a neuromuscular fellowship at the University of Michigan. Dr. Donofrio is board certified in Neurology, Internal Medicine, EMG and Neuromuscular Disorders. He is Chief of the Neuromuscular Section and Director of the EMG lab at Vanderbilt.

Other duties include Directorship of the MDA Clinic and the ALS Clinic. He is a member of the Medical Advisory Committee of the GBS/CIDP International Foundation; Vanderbilt University Medical Center is a certified Center of Excellence for the GBS/CIDP International Foundation. Dr. Donofrio has a special interest in all types of peripheral neuropathies, particularly GBS and CIDP, but also cares for many patients with myasthenia gravis, ALS, and muscle disorders. He is the author of the textbook entitled The Textbook of Peripheral Neuropathy published in April 2012 by Demos Medical.

VIDEO & RESOURCES

  • 25:18
    Incidence of GBS and CIDP Following Influenza Vaccination

    Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

Karissa Gable, MD
Karissa Gable, MD

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina
BIO

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina. She is a graduate of the University of North Carolina at Chapel Hill School of Medicine and pursued a residency in Neurology at Northwestern University and a Neuromuscular fellowship at Harvard Medical School. Dr. Gable is board certified in Neurology, Electrodiagnostic Medicine and Neuromuscular Disorders.

Dr. Gable has a special interest in all types of peripheral neuropathies, particularly GBS and CIDP, but also cares for many patients with myasthenia gravis and muscle disorders. Other duties include Directorship of the Neuromuscular Fellowship Program at Duke University.

VIDEO & RESOURCES

  • 09:29
    Fatigue in CIDP
    Engage in a presentation on the comparison between active and remission disease states in CIDP.

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark
BIO

Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International. His neurology training was at Aarhus University Hospital and he is currently completing a neuromuscular fellowship at Johns Hopkins Hospital in Baltimore, MD, USA. His research has helped establish the role of SCIG in the treatment of CIDP.
VIDEO & RESOURCES

  • 15:18
    Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
    Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.

Carol L. Koski, MD

GBS/CIDP Foundation International
BIO

Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International. She received her medical degree from the University of Maryland, Baltimore, Maryland. She is an expert on GBS and CIDP, and has played a key role in facilitating research over the past decade which has led to advances in the understanding of inflammatory neuropathies.
VIDEO & RESOURCES

  • 5:51
    IgG Levels and Wear Off Reflect Administration and Outcome
    Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IV- or SCIg-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
Richard A. Lewis, MD
Richard A. Lewis, MD

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA
BIO

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program. He is Director of the GBS-CIDP Foundation Center of Excellence at Cedars-Sinai. Prior to his move to California in 2013, he was Associate Chair of Neurology at Wayne State University where he had been for 19 years.

He has been on the Board of Directors of the Peripheral Nerve Society, and on the Steering Committee of the Inflammatory Neuropathy Consortium. He is on the Medical Advisory Boards of the GBS-CIDP Foundation and the Myasthenia Gravis Foundation. He has been involved as an investigator, steering committee member and DSMB member in clinical trials in a number of immune mediated disorders including CIDP, myasthenia gravis and multifocal motor neuropathy.

VIDEO & RESOURCES

  • 13:53
    Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

    Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

Michael Lunn, PhD
Michael Lunn, PhD

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

BIO

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery. He trained in medicine at Emmanuel College, Cambridge and the Charing Cross and Westminster Hospitals Medical School. He worked at the Royal Brompton and Hammersmith Hospitals before receiving his specialist neurology training in the UK at Guy’s, King’s, St Thomas’ and Charing Cross Hospitals, Hurstwood Park Neurosciences Centre and Queen Square, and at the Johns Hopkins Hospital in Baltimore, USA. He was appointed to a Consultant position at NHNN in 2005.

VIDEO & RESOURCES

  • 14:01
    Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

    Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Nabil Moumane, MD
Nabil Moumane, MD

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring
BIO

Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring. He completed his medical training at the University of Casablanca in Morocco. He also has a Master of Biomedical and Physical Engineering of Health in the University of Saints-Pères, Paris, and Biostatistics for the Health and Biological Sciences in Pierre at Marie Curie University in Paris. Before joining the pharmaceutical industry he spent 3 years in Emergency department. He gained over 10 years of industry experience in Medical Affairs departments first in central nervous system and psychiatry and then, from 2010 he joined CSL Behring as a medical manager in immunology.

VIDEO & RESOURCES

  • 3:00
    Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

    Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Back to Top